In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blueprint Medicines Corp.

www.blueprintmedicines.com

Latest From Blueprint Medicines Corp.

Ipsen’s Palovarotene Hit By FDA Clinical Hold

The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.

Clinical Trials Safety

Ipsen CBO: We Are Seeking Fresh Rare Disease Buys

Ipsen’s chief business officer tells Scrip that buying Canada’s Clementia Pharmaceuticals this year gave the French group’s rare disease operations an “anchor asset” to build on.

Commercial Companies

Welcome To Alexion 2.0

In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.

C-Suite Speaks Outlook 2020

Ipsen Doubles Down On FOP With Blueprint Pact

With the addition of BLU-782 to its soon-to-be filed fibrodysplasia ossificans progressiva drug palovarotene, Ipsen hopes to expand treatment options for patients with the rare bone disease.

Companies Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Blueprint Medicines Corp.
  • Senior Management
  • Jeffrey Albers, Pres. & CEO
    Mike Landsittel, CFO
    Marion Dorsch, PhD, CSO
    Anthony Boral, MD, PhD, CMO
    Kathryn Haviland, COO
  • Contact Info
  • Blueprint Medicines Corp.
    Phone: (617) 374-7580
    45 Sydney St.
    Ste. 200
    Cambridge, MA 02139
    USA
UsernamePublicRestriction

Register